Today: 14 May 2026
Browse Category

Pharmaceuticals 30 December 2025 - 1 January 2026

Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

Pfizer shares fell 0.4% to $24.90 in after-hours trading after reports the company will lead U.S. drug list-price increases in 2026, including a 15% hike for its COVID vaccine. Healthcare data show Pfizer plans about 80 price increases, as drugmakers prepare for the annual January price reset under political scrutiny. Investors await further pricing updates and Pfizer’s February earnings call.
1 January 2026
···
Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next

Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next

Corcept shares plunged nearly 50% to $35.31 after the FDA rejected relacorilant for Cushing’s-related hypertension, citing insufficient evidence of effectiveness. The move erased about $3.7 billion in market value. Corcept said it will meet with the FDA to discuss next steps. The company is also awaiting a July 2026 FDA decision on relacorilant in ovarian cancer.
31 December 2025
··
Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly shares slipped 0.1% to $1,078.95 by early afternoon Wednesday after reports of price cuts for its diabetes and obesity drugs in China and a planned U.S. list-price reset. A regulatory filing showed Lilly Endowment, the company’s largest shareholder, trimmed its stake slightly. Investors focused on pricing pressure as the company’s GLP-1 drugs face broader access and lower prices heading into 2026.
31 December 2025
···
Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus

Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus

Genmab A/S shares fell 3.3% to $30.44 in New York after the company dropped further development of acasunlimab, a late-stage cancer drug, following a portfolio review. Genmab said the move does not affect its 2025 guidance and will focus on other pipeline drugs. The company also completed its acquisition of Merus N.V., paying $97 per share in a tender offer. Merus requested Nasdaq delist its stock after the merger.
31 December 2025
···
Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers Health shares fell 0.5% to $32.87 in premarket trading Wednesday after closing down 3.1% the previous session. The move follows price cuts by Novo Nordisk and Eli Lilly on obesity drugs in China, raising questions about future margins and demand for GLP-1 therapies. Hims recently launched its weight-loss membership in the UK, offering access to Wegovy and Mounjaro.
31 December 2025
····
Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Vanda Pharmaceuticals shares rose about 18% in premarket trading after the FDA approved its motion-sickness drug Nereus (tradipitant). The company plans to launch the oral treatment in the coming months. The approval followed late-stage trials involving 681 patients. Shares closed at $7.03 Tuesday and were indicated around $8.30 early Wednesday.
31 December 2025
···
Pfizer stock flat after hours as TD Cowen sticks with Hold; Feb. 3 results ahead

Pfizer stock flat after hours as TD Cowen sticks with Hold; Feb. 3 results ahead

Pfizer shares slipped 0.02% to $24.99 in late after-hours trading Tuesday. TD Cowen reiterated a Hold rating and $30 price target, citing weak longer-term trends. Investors await Pfizer’s next results for signs it can offset declining COVID sales and upcoming patent expirations. Pfizer forecasts 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00.
31 December 2025
···
JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal

JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal

Johnson & Johnson closed its $3.05 billion cash acquisition of Halda Therapeutics, adding the RIPTAC oncology platform and lead prostate cancer program. Shares slipped 0.3% to $206.91 in after-hours trading. The company expects about $0.20 dilution to adjusted EPS, split between 2025 and 2026, and will discuss 2026 guidance on its Jan. 21 earnings call.
31 December 2025
··
Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly shares edged up 0.1% after hours to $1,079.75 following news it and Novo Nordisk are cutting prices on top obesity drugs in China. Novo confirmed Wegovy price reductions; a hospital WeChat post showed Mounjaro’s 10mg pen dropping to 445 yuan ($63) from 2,180 yuan. Novo’s U.S. shares slipped about 0.5%. Lilly Endowment Inc. disclosed selling 3,593 shares in a regulatory filing.
30 December 2025
···
Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals shares fell 3% to $23.33 in thin afternoon trading Tuesday, extending a two-day slide and leaving the stock about 12% below its June high. Biotech ETFs underperformed the broader market, with the iShares Nasdaq Biotechnology ETF down 1.2%. Investors are awaiting the Federal Reserve’s meeting minutes and Catalyst’s next update in January.
30 December 2025
··
1 … 21 22 23 24 25 … 40

Stock Market Today

  • ABNB and BKNG Outperform Hyatt Hotels in Valuation and Growth Metrics
    May 14, 2026, 4:13 AM EDT. In the Hotels, Resorts & Cruise Lines industry, Airbnb (ABNB) and Booking Holdings (BKNG) show lower valuation and higher revenue and operating income growth compared to Hyatt Hotels (H). ABNB and BKNG trade at price-to-operating-income ratios (P/OpInc) of 30.7x and 12.9x respectively, versus Hyatt's 32.7x, while delivering stronger latest twelve months (LTM) and three-year average growth. Hyatt's LTM operating income growth stands at -0.4%, lagging ABNB's 4.1% and BKNG's 21.3%. Market capitalizations also differ notably, with Hyatt at $15.8 billion, ABNB at $79.5 billion, and BKNG at $122.5 billion. Despite strong growth elsewhere, Hyatt's higher valuation and weaker recent income growth suggest investors may favor ABNB and BKNG stocks. Multi-factor analysis remains essential before investment decisions.

Latest articles

Nvidia’s China H200 Chip Door Just Opened. The Money Still Isn’t Moving

Nvidia’s China H200 Chip Door Just Opened. The Money Still Isn’t Moving

14 May 2026
The U.S. has approved Nvidia to sell H200 AI chips to about 10 Chinese firms, including Alibaba and Tencent, but no shipments have occurred as Chinese buyers hold back under Beijing’s guidance. Nvidia CEO Jensen Huang is in Beijing with President Trump’s delegation ahead of the company’s May 20 earnings report. Lenovo confirmed it is cleared to distribute the chips in China.
Nokia Stock Surges Again as Cisco’s AI Orders Put New Heat Under the Network Trade

Nokia Stock Surges Again as Cisco’s AI Orders Put New Heat Under the Network Trade

14 May 2026
Nokia shares jumped about 10% in Helsinki Thursday, extending gains after Cisco reported $5.3 billion in AI infrastructure orders and raised its full-year outlook. Nokia launched new agentic AI tools for broadband networks and named Siemens executive Emma Falck as president of Mobile Infrastructure. The stock approached levels last seen 16 years ago.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 14.05.2026

14 May 2026
LIVEMarkets rolling coverageStarted: May 14, 2026, 12:00 AM EDTUpdated: May 14, 2026, 4:21 AM EDT ABNB and BKNG Outperform Hyatt Hotels in Valuation and Growth Metrics May 14, 2026, 4:13 AM EDT. In the Hotels, Resorts & Cruise Lines industry, Airbnb (ABNB) and Booking Holdings (BKNG) show **lower valuation** and **higher revenue and operating income growth** compared to Hyatt Hotels (H). ABNB and BKNG trade at price-to-operating-income ratios (P/OpInc) of 30.7x and 12.9x respectively, versus Hyatt's 32.7x, while delivering stronger latest twelve months (LTM) and three-year average growth. Hyatt's LTM operating income growth stands at -0.4%, lagging ABNB's 4.1% and
Go toTop